Introduction {#sec1-1}
============

Tinea is a superficial fungal infection caused by dermatophytes which invade and multiply within the keratinized tissue (skin, hair, nails). Approximately 20%-25% of the world population is affected by tinea.\[[@ref1]\] There is a rise in the prevalence in recent years especially in the tropical countries\[[@ref2]\] along with an increase in the number of chronic and recurrent dermatophytosis. There is a huge gap between the treatment required in the present scenario and the treatment guidelines given in the standard books.\[[@ref3][@ref4][@ref5]\]

There is a paucity of original studies especially in India depicting dermatophytosis becoming a huge menace both to the patient and to the treating physician. Terbinafine is a fungicidal drug and acts by inhibiting the enzyme squalene epoxidase which converts squalene to lanosterol. Itraconazole is basically a fungistatic drug that acts through inhibition of the enzyme 14α-demethylase. Many dermatologists have started using higher doses and combination regimens of antifungals to counter this problem. However, such regimens have not been validated. Hence, in this study we decided to evaluate the commonly used systemic antifungal drugs, i.e., terbinafine and itraconazole, at various doses and in combination.

Materials and Methods {#sec1-2}
=====================

The study design was a randomized parallel group open labeled trial conducted at a tertiary healthcare center. The study was conducted between August 2018 and July 2019. The trial was approved by the Institutional Ethics Committee. This trial was registered with CTRI (CTRI/2018/07/015063).

Participant's inclusion criteria were KOH positive cases of tinea cruris, corporis and faciei.

Exclusion criteria were: (a) pregnancy and lactation, (b) children less than 12 years of age, (c) weight less than 40 kg and more than 80 kg, (d) any history of drug reaction or allergy to any of the two drugs, (e) any significant abnormality in complete blood counts (CBC), liver function test (LFT), renal function test (RFT) and electrocardiogram (ECG), (f) history of intake of oral antifungal agents in the last one month, (g) patient with any other disease requiring systemic therapy and (h) patients with co-morbidities like cardiac disorder, liver disorder, renal disorder.

Intervention: Five parallel study groups were as follows:

Terbinafine 250 mg/day: T 250Itraconazole 200 mg/day in two divided doses: I 200Terbinafine 250 mg + Itraconazole 200 mg: T + ITerbinafine 500 mg/day in two divided doses: T 500Itraconazole 400 mg/day in two divided doses: I 400.

Treatment and follow-up:

A written and informed consent was taken from each patient or his/her guardian. Patients were prescribed the allocated antifungal drug. Topical antifungal was not prescribed. The clinical improvement was assessed based on total body surface area involved (BSA) at each visit. The enrolled patients were called for follow up at every two weeks for a total of 8 weeks or till complete clearance of lesions. Investigations done at baseline were CBC, LFT, RFT, and ECG. At every second visit, LFT and ECG were repeated in the itraconazole groups and LFT and CBC in the terbinafine group. RFT was done at every second visit for all the groups. In the combination group, LFT, CBC and ECG were repeated at every second visit. Fungal culture and sensitivity of the skin scrapings were done by the disk diffusion method for all patients.
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### Outcome measures and statistical analysis {#sec3-1}

Patients were labeled as the following at both fourth and eighth weeks.

Primary outcome: Cured (complete clinical resolution of all lesions)Secondary outcome: Partially cured (more than 50% improvement in the total BSA) and failure (increase in severity of the lesions or no improvement in the lesions after 4 weeks of staring antifungal agents).

Note: Partially cured and failure measures as secondary outcomes were added after commencement of the trial.

### Sample size calculation {#sec3-2}

The sample size was calculated with 95% level of confidence, power of 80% and considering cure rates of 65% and 90%. By taking 1:1 allocation and considering the dropout rates to be 10%, the final sample size calculated was 275.

### Randomization {#sec3-3}

Participants were randomized equally in a 1:1 allocation (unstratified) into five parallel treatment groups by a computer-generated random number sequence using the MS Excel software and one of the author assigned participants to the interventions. Blinding was not done.

### Statistical analysis {#sec3-4}

Parametric one-way analysis of variance (*F* test) was applied to find out the mean differences among five treatment groups. Chi-square test was used to find out significant difference in the proportions among treatment groups and it was also used to test the significance of change from baseline to various follow-up within the groups. A *P* value less than 0.05 was considered as significant. Patients who were excluded from the study due to adverse events or lost to follow-up were not included in the data for statistical analysis.

Clinico-mycological correlation was done at the end of the study.

Results {#sec1-3}
=======

A total of 324 patients were screened and 275 patients (55 in each group) of tinea cruris, corporis and faciei were enrolled in the study \[[Figure 1](#F1){ref-type="fig"}\]. The mean age of the patients was 29.36 ± 11.37 years. Majority of the patient (36.4%) belonged to 21 to 30 years of age. The disease was more common in males (74.1%) and male to female ratio was 2.8:1. Majority of the patients had BSA less than 5% (69.9%) and 81.2% had the disease for 1-6 months duration. Most of the patients weighed 51 to 60 kg (35%). The patient characteristics were comparable in all the groups \[[Table 1](#T1){ref-type="table"}\]. In this study, 81.7% had used topical corticosteroid either alone or in combination with an antifungal and/or antibiotic. Topical antifungal only creams were used by 10.1% and 8.05% did not apply any topical agent. Most common clinical variant was tinea corporis and cruris (69%) \[[Table 2](#T2){ref-type="table"}\].

![Flowchart of the study](IJD-65-284-g001){#F1}

###### 

Patient baseline characteristics (*n*=236)

  Characteristics          Groups         *P*                                                         
  ------------------------ -------------- -------------- -------------- -------------- -------------- -------
  Age (years) (Mean±SD)    32.45±11.411   28.06±12.541   29.67±10.125   27.02±10.680   29.65±11.733   0.187
  Male (%)                 70.2           72.3           75.0           68.8           84.8           0.417
  Female (%)               29.8           27.7           25.0           31.3           15.2           
  Weight (kg) (Mean±SD)    61.85±10.685   58.70±9.666    61.33±8.873    61.65±9.723    63.72±10.195   0.188
  Baseline BSA (Mean±SD)   5.21±4.288     7.49±11.371    4.40±3.187     5.25±4.071     5.43±4.385     0.169

###### 

Clinical variants of tinea (*n*=236)

  Diagnosis                           Total *n* (%)
  ----------------------------------- ---------------
  T. corporis *et* cruris             163 (69)
  T. corporis et cruris *et* faciei   34 (14.4)
  T. cruris                           21 (8.8)
  T. corporis                         15 (6.3)
  T. faciei                           2 (0.8)
  T. corporis *et* faciei             1 (0.4)

T: Tinea

Out of 275 samples cultured at baseline, fungal growth was seen in 111 samples (40.3%). The most common growth observed was of *Trichophyton mentagrophytes* (72.9%). *T. interdigitale* was found in 25 (22.5%) and a combination of *T. mentagrophytes* and *T. interdigitale* was detected in four cases. Only a single strain of *Trichophyton rubrum* was isolated. Ninety nine (89%) isolates were sensitive to itraconazole and only 28 (25.2%) isolates were sensitive to terbinafine. Two hundred thirty-six patients completed the study, rest were excluded due to adverse events or lost to follow-up. The outcome of the study was assessed at 4 and 8 weeks. At 4 weeks, 2 (4.3%), 8 (17%), 9 (18.9%), 3 (6.3%) and 9 (19.6%) were cured with T 250, I 200, I + T, T 500 and I 400 respectively (*P* \< 0.001). At 8 weeks, 11 (23.4%), 36 (76.6%), 38 (79.2%), 16 (33.3%) and 37 (80.4%) were cured respectively (*P* \< 0.001).

At 4 weeks, 38.3%, 70.2%, 68.8%, 45.8% and 71.7% were partially cured among T 250, I 200, I + T, T 500 and I 400 groups respectively. At 8 weeks, the figures were 19.1%, 10.6%, 8.3%, 18.8% and 10.9%, respectively. Itraconazole containing groups showed statistically highly significant cure rates than terbinafine only groups at both 4 and 8 weeks. Cure rates of I 200 vs I 400 vs I + T against each other were not significant. The outcome between T 250 and T 500 was also not statistically significant. Cure rates at 8 weeks were found to be greater than that at 4 weeks for all groups, which was found to be highly significant.

Lichenoid drug eruption and acute urticaria developed in one patient each in T-250 group. One patient in each group taking itraconazole developed increased liver enzymes (AST/ALT more than two times the upper limit of normal) and one patient developed erectile dysfunction in I 400 group.

One of the most important aspects of the study was the clinico-mycological correlation, which was done at the end of the study. Eighty three culture positive cases completed the study. A good clinical correlation was seen with majority of the sensitivity results. However, some exceptions were noted. Out of the 72 isolates sensitive to itraconazole five did not respond to itraconazole. Two out of 11 isolates resistant to itraconazole responded to treatment, both were cured. One out of 20 isolates sensitive to terbinafine failed to respond to terbinafine. Two out of the 63 isolates which were resistant to terbinafine, responded to treatment with terbinafine. One patient got cured completely and the other got partially cured.

Discussion {#sec1-4}
==========

There has been a drastic change in the Indian scenario of dermatophytosis with increase in the occurrence, relapse, recurrence and chronicity in the recent years which have added to the morbidity. This may partly be attributed to the injudicious use of oral antifungals and the rampant misuse of topical steroids due to easy availability of over-the-counter (OTC) topical steroid combination products.\[[@ref6]\] The patients, pharmacists, quacks and few general physicians have a nonchalant attitude toward the use of these OTC products, which have led to an epidemic of "steroid-modified tinea".\[[@ref7]\] Older effective antifungals in literature seem to have lost their efficacy and the standard treatment recommendations for treatment of tinea seem to be no longer valid.

The most common age group involved in this study was 21-30 years of age (36.4%) with mean of 29.36 ± 11.37 year, which is similar to that of the previous studies.\[[@ref8][@ref9][@ref10][@ref11][@ref12]\] Male:Female ratio was approximately 2.8:1. This may be attributed to the fact that males are mostly involved in outdoor physical activities, which lead to excessive sweating making a favorable environment for the fungal infections. Tinea may be underdiagnosed in females and their treatment-seeking behavior is also less. This finding of male predominance is similar to other previous studies, in which M:F ratio varied from 2-4:1.\[[@ref13][@ref14]\] Most common clinical variant was tinea corporis and cruris (69%). Mahajan *et al.* also reported mixed tinea corporis and cruris infection as the commonest form.\[[@ref15]\] In this study, 81.7% had used topical corticosteroid either in combination with an antifungal, an antibiotic or alone.

Fungal growth was seen in 111 out of 275 samples (40.3%). There is a wide variation in the yield of the fungus in the culture. Most studies reported higher yield, greater than 40%\[[@ref13][@ref16][@ref17][@ref18]\] and some reported yield less than 40%.\[[@ref19][@ref20]\] The most common growth observed was of *Trichophyton mentagrophytes* (30.7%). Previously *Trichophyton rubrum* used to be the most common species but now as observed in the recent studies *Trichophyton mentagrophytes* has emerged as a dominant one.\[[@ref15][@ref21][@ref22][@ref23]\] Ajello mentioned that fungal strains causing dermatophytoses not only differed from region to region but might change with the passage of time.\[[@ref24]\] Antifungal susceptibility was done using disk diffusion method. Many studies have shown a good correlation between disk diffusion method and Clinical Laboratory Standard Institute (CLSI) micro broth dilution method.\[[@ref25][@ref26][@ref27]\] Ninety-nine (89%) isolates were sensitive to itraconazole and only 28 (25.2%) isolates were sensitive to terbinafine. Singh *et al.* has reported 82% of 44 strains of dermatophyte resistant to terbinafine and 15% of strains resistant to itraconazole.\[[@ref23]\] Molecular resistance to terbinafine due to mutation of squalene epoxidase gene has been reported.\[[@ref28][@ref29]\]

In this study, itraconazole was the more effective drug. Majid *et al.*\[[@ref30]\] reported a cure rate of 65% with terbinafine 250 mg daily after 2 weeks; Singh and Shukla\[[@ref31]\] reported a decreased cure rate of 30% after 4 weeks and in this study the cure rate has further plummeted down to 23% even after 8 weeks. This finding is consistent with the decreased response observed with terbinafine-treated patients. The cure rate of terbinafine 500 was 33%, which was not found to be significantly different from that of T-250. This finding is in contrast to that seen by Bhatia *et al.*\[[@ref32]\] who reported a cure rate of 74%. In a retrospective study by Babu *et al.*, 80% of patients showed more than 75% improvement with terbinafine 500 mg daily.\[[@ref33]\] Multidrug therapy and increasing the dose do not seem to have any added benefit.

Tearaki and Shiohara\[[@ref34]\] and Zheng *et al.*\[[@ref35]\] have reported lichenoid drug eruption following terbinafine. FDA has mentioned decreased libido as an adverse drug reaction with itraconazole occurred in clinical trials with an incidence of 1%. Bailey *et al.* and Tucker *et al.* have reported erectile dysfunction as a rare side effect following itraconazole intake.\[[@ref36][@ref37]\] FDA stated liver function abnormalities occurred in 3% of the patients in the clinical trials. In our study, derangement of liver enzymes occurred in 1.27% of patients taking itraconazole. On clinico-mycological correlations, most of the patients with sensitive isolates responded with respective drugs. Few patients did not respond. On the other hand few patients responded while their isolates were resistant to a particular drug. This discrepancy of results may be due to a multitude of factors, such as drug pharmacokinetics, pharmacodynamics, host response, local treatment of the infection site. This prompted Rex and Pfaller to coin the phrase the 90-60 rule.\[[@ref38]\] In general if a microbe is found to be susceptible to a drug, 90% of patients are likely to have a favorable therapeutic response. In contrast to with resistant strain, nearly 60% of patients may be expected to respond to therapy.

Dosage of terbinafine according to body weight is approved for tinea capitis. Singh *et al.* has used 5 mg/kg body weight for the treatment of tinea corporis, cruris, faciei in children and adults.\[[@ref31]\] Itraconazole dosage of 5 mg/kg body weight has been used in children and infants with superficial dermatophytosis and found to be effective and safe.\[[@ref39][@ref40]\] In adults a fixed-dose regimen of 250 mg/day terbinafine and 200 mg/day itraconazole is recommended.\[[@ref3][@ref4]\]

The sudden increase in the number of recalcitrant tinea in India is of major concern. Antifungals no longer seem to work like they used to previously. Itraconazole is the most effective antifungal drug against dermatophytes and longer duration of treatment is required for complete cure of the disease. Use of higher doses of both terbinafine and itraconazole or combination does not seem to have any additional benefit. Results of antifungal susceptibility tests predict the clinical outcome in majority of the cases. The decline in the efficacy of antifungal is of grave concern. The reasons are not fully understood but many speculate it to be due to use of OTC topical steroid combination products, misuse of drugs and development of resistance. It is crucial that the use of OTC products and misuse of these drugs should be reduced. In the coming years just like terbinafine, there is a chance that efficacy of itraconazole may drop as well leaving us with very limited armamentarium of drugs that can be used.

The limitations of the study were non-blinding and use of fixed doses although variation in the weights of subjects. Long follow-up for recurrences also was not done.
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